ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation
Conditions
- Stable Coronary Artery Disease
- Acute Coronary Syndrome
- Percutaneous Coronary Intervention
Interventions
- GENETIC: Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers
Sponsor
Ottawa Heart Institute Research Corporation
Collaborators